 |
Return Create A Forum - Home |
 |
--------------------------------------------------------- |
|
MS Speaks |
 |
https://msspeaks.createaforum.com |
|
--------------------------------------------------------- |
|
***************************************************** |
|
Return to: NOVANTRONE (mitoxantrone) |
|
***************************************************** |
|
#Post#: 586-------------------------------------------------- |
|
(Abst.) Lack of efficacy of mitoxantrone in PPMS |
|
By: agate Date: December 12, 2014, 3:20 pm |
|
--------------------------------------------------------- |
|
I can't determine how "peer-reviewed" the Journal of |
|
Neuroimmunology is but this abstract concerns mitoxantrone, and |
|
there hasn't been much about it lately. |
|
From PubMed, December 4, 2014: |
|
[quote]J Neuroimmunol. 2014 Nov 20. pii: S0165-5728(14)00978-3. |
|
doi: 10.1016/j.jneuroim.2014.11.017. |
|
Lack of efficacy of mitoxantrone in primary progressive multiple |
|
sclerosis irrespective of pharmacogenetic factors: A |
|
multi-center, retrospective analysis |
|
Grey N�e Cotte S1, Salmen N�e Stroet A1, von Ahsen N2, Starck |
|
M3, Winkelmann A4, Zettl UK4, Comabella M5, Montalban X5, Zipp |
|
F6, Fleischer V6, Kruse N7, Gold R1, Chan A8. |
|
Author information |
|
1Department of Neurology, St. Josef-Hospital, Ruhr University, |
|
Bochum, Germany. |
|
2Department of Clinical Chemistry, Medical Faculty, University |
|
of G�ttingen, Germany. |
|
3Marianne-Strau�-Klinik, Berg, Germany. |
|
4Department of Neurology, University of Rostock, Germany. |
|
5Department of Neurology-Neuroimmunology, Centre |
|
d'EsclerosiM�ltiple de Catalunya (Cemcat), Institut de |
|
RecercaValld'Hebron (VHIR), Hospital UniversitariValld�Hebron, |
|
UniversitatAut�noma de Barcelona, Spain. |
|
6University Medicine Mainz, Johannes Gutenberg University Mainz, |
|
Department of Neurology, Germany. |
|
7Institute of Neuropathology, University Medical Center |
|
G�ttingen, Germany. |
|
8Department of Neurology, St. Josef-Hospital, Ruhr University, |
|
Bochum, Germany. Electronic address: [email protected]. |
|
BACKGROUND: |
|
Mitoxantrone is used on an off-label basis in primary |
|
progressive MS (PPMS). ABC-transporter-genotypes are associated |
|
with therapeutic response in relapsing/secondary progressive MS |
|
(RP/SPMS). |
|
OBJECTIVE: |
|
To evaluate potential pharmacogenetic response markers for |
|
mitoxantrone in PPMS. |
|
METHODS: |
|
41 mitoxantrone-treated PPMS-patients, 155 mitoxantrone-treated |
|
RP/SPMS-patients and 43 PPMS-controls were retrospectively |
|
assessed for clinical therapy-response and in correlation with |
|
four single-nucleotide-polymorphisms in ABCB1- and ABCG2-genes. |
|
RESULTS: |
|
53.7% PPMS-patients were mitoxantrone-responders, in comparison |
|
to 78.1% of RP/SPMS-patients (p=0.039). There was no association |
|
between genotype and treatment response. |
|
CONCLUSION: |
|
Our data discourages the use of mitoxantrone in PPMS regardless |
|
of pharmacogenetic response markers previously described in |
|
RP/SPMS. |
|
PMID: 25468777[/quote] |
|
The abstract can be seen here |
|
http://www.ncbi.nlm.nih.gov/pubmed/25468777. |
|
***************************************************** |
